Three months after Myogen Inc.'s lead drug candidate for heart failure, enoximone, missed statistical significance in the primary endpoint of a Phase III trial - an event the company blamed on unexpected improvements in patients given placebo - the compound has failed in top-line results from two more Phase III studies. (BioWorld Today) Read More
